General Archive
-
News releases, Ventures funding
LifeArc co-founded company RQ Bio signs licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-CoV-2
LONDON, UK, 17 May 2022 — LifeArc today announced that RQ Biotechnology Ltd (RQ Bio), a company it co-founded, has…
-
News releases
LifeArc bolsters scientific leadership by appointing new Chief Scientific Officer
Welcome to Dr Dave Powell, who has joined LifeArc as our first Chief Scientific Officer (CSO). Dave is an experienced scientist and leader, with exceptional translational…
-
News releases, Ventures funding
LifeArc unveils new strategy and £1.3 billion spend to drive life-changing science
Aims to transform the way diseases such as motor neurone disease are prevented, identified and treated.
-
News releases
MRCT and Chinese National Centre collaborate on malaria
MRCT’s Drug Discovery Group has developed a drug screening assay for a potential Malaria drug target called PfSub-1, a subtilisin-like…
-
News releases
MRC to receive over USD200m
The Medical Research Council is to receive over US$200m as part of one of the biggest deals to come out…